News

Theradiag snaps up Prestizia
Enlarge image

BusinessFrance

Theradiag snaps up Prestizia

28.06.2012 - French theranostics and in vitro diagnostics company Theradiag is set to acquire its compatriot Prestizia, a specialist for microRNA-based diagnostics.

Paris/Marne la Vallee – Prestizia SAS is part of the Holding Incubatrice Biotechnology and Pharmacy, which was launched by Truffle Capital in 2010 and is presided by Jean-Jacques Bertrand, former CEO of Aventis-Pasteur. The company, which has been set up in April 2011 with a starting capital of €300,000, aims at developing novel diagnostic assays for viral infections and human malignancies based on microRNA expression and holds an exclusive license to a technology for characterising HIV cell tropism based on the identification of microRNA signatures.

“The acquisition of Prestizia represents a major advance for Theradiag. Its microRNA platform is going to allow us to strengthen our development in theranostics with a highly innovative, patented technology,” stated Michel Finance, CEO of Theradiag. The Marne la Vallee-based company changed its name from Biomedical Diagnostics (BMD) only last month, to reflect its drive to develop theranostic assays for monitoring the effects of biotherapeutics.

Theradiag pins primary hopes on the newly acquired microRNA technology, stating that it could have widespread clinical applications including identifying patients eligible for particular anti-HIV treatments or for differentiating different cancer types. The first application of this platform is already being developed, in collaboration with the Institut de Génétique Moléculaire de Montpellier (IGMM) for finalising a molecular biology test of HIV tropism to be marketed in the near future.

http://www.european-biotechnology-news.com/news/news/2012-02/theradiag-snaps-up-prestizia.html

BusinessGermany

19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

BusinessDenmark

04.09.2014 After their arthritis product’s Phase IIb failure, Novo Nordisk A/S is pulling out of all research and development activities within inflammatory disorders.

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.09 CHF12.50%
  • MERCK KGAA72.63 EUR4.35%
  • MAGFORCE7.30 EUR4.29%

FLOP

  • CYTOS0.21 CHF-8.70%
  • WILEX2.22 EUR-5.93%
  • CO.DON3.08 EUR-5.81%

TOP

  • PAION3.25 EUR31.0%
  • CO.DON3.08 EUR23.2%
  • EPIGENOMICS3.80 EUR22.6%

FLOP

  • CYTOS0.21 CHF-19.2%
  • ADDEX3.25 CHF-18.8%
  • MEDIGENE3.86 EUR-17.0%

TOP

  • SANTHERA89.30 CHF2088.7%
  • CO.DON3.08 EUR234.8%
  • PAION3.25 EUR221.8%

FLOP

  • CYTOS0.21 CHF-94.8%
  • BIOFRONTERA2.24 EUR-38.6%
  • 4SC1.14 EUR-38.4%

No liability assumed, Date: 22.09.2014